

- 520.2340 Tepoxalin.
 520.2345 Tetracycline.
 520.2345a Tetracycline hydrochloride capsules.
 520.2345b Tetracycline tablets.
 520.2345c Tetracycline boluses.
 520.2345d Tetracycline powder.
 520.2345e Tetracycline oral liquid.
 520.2345f Tetracycline phosphate complex and sodium novobiocin capsules.
 520.2345g Tetracycline hydrochloride and sodium novobiocin tablets.
 520.2345h Tetracycline hydrochloride, sodium novobiocin, and prednisolone tablets.
 520.2362 Thienium closylate tablets.
 520.2380 Thiabendazole oral dosage forms.
 520.2380a Thiabendazole top dressing and mineral protein block.
 520.2380b Thiabendazole drench or oral paste.
 520.2380c Thiabendazole bolus.
 520.2380d Thiabendazole, piperazine citrate suspension.
 520.2380e Thiabendazole with trichlorfon.
 520.2380f Thiabendazole, piperazine phosphate powder.
 520.2455 Tiamulin.
 520.2471 Tilmicosin.
 520.2473 Tioxidazole oral dosage forms.
 520.2473a Tioxidazole granules.
 520.2473b Tioxidazole paste.
 520.2475 Toceranib.
 520.2481 Triamcinolone acetonide tablets.
 520.2482 Triamcinolone acetonide oral powder.
 520.2483 Triamcinolone.
 520.2520 Trichlorfon oral dosage forms.
 520.2520b Trichlorfon and atropine.
 520.2520e Trichlorfon boluses.
 520.2520f Trichlorfon granules.
 520.2520g Trichlorfon, phenothiazine, and piperazine dihydrochloride powder.
 520.2582 Triflupromazine hydrochloride tablets.
 520.2598 Trilostane.
 520.2604 Trimeprazine tartrate and prednisolone tablets.
 520.2605 Trimeprazine tartrate and prednisolone capsules.
 520.2610 Trimethoprim and sulfadiazine tablets.
 520.2611 Trimethoprim and sulfadiazine paste.
 520.2612 Trimethoprim and sulfadiazine suspension.
 520.2613 Trimethoprim and sulfadiazine powder.
 520.2640 Tylosin.
 520.2645 Tylvalosin.

AUTHORITY: 21 U.S.C. 360b.

SOURCE: 40 FR 13838, Mar. 27, 1975, unless otherwise noted.

§ 520.23 Acepromazine.

(a) *Specifications.* Each tablet contains 5, 10, or 25 milligrams (mg) acepromazine maleate.

(b) *Sponsors.* See No. 000010 in § 510.600(c) of this chapter.

(c) *Conditions of use*(1) *Dogs*—(i) *Amount.* 0.25 to 1.0 mg per pound (lb) body weight orally.

(ii) *Indications for use.* As an aid in tranquilization and as a preanesthetic agent.

(iii) *Limitations.* Federal law restricts this drug to use by or on the order of a licensed veterinarian.

(2) *Cats*—(i) *Amount.* 0.5 to 1.0 mg/lb body weight orally.

(ii) *Indications for use.* As a tranquilizer.

(iii) *Limitations.* Federal law restricts this drug to use by or on the order of a licensed veterinarian.

[75 FR 10165, Mar. 5, 2010]

§ 520.28 Acetazolamide sodium soluble powder.

(a) *Specifications.* The drug is in a powder form containing acetazolamide sodium, USP equivalent to 25 percent acetazolamide activity.

(b) *Sponsor.* See No. 053501 in § 510.600(c) of this chapter.

(c) *Conditions of use.* (1) It is used in dogs as an aid in the treatment of mild congestive heart failure and for rapid reduction of intraocular pressure.¹

(2) It is administered orally at a dosage level of 5 to 15 milligrams per pound of body weight daily.¹

(3) For use only by or on the order of a licensed veterinarian.¹

[40 FR 13838, Mar. 27, 1975, as amended at 67 FR 78355, Dec. 24, 2002. Redesignated at 78 FR 66264, Nov. 5, 2013]

§ 520.38 Albendazole oral dosage forms.

§ 520.38a Albendazole suspension.

(a) *Specifications.* Each milliliter of suspension contains 45.5 milligrams

¹These conditions are NAS/NRC reviewed and deemed effective. Applications for these uses need not include effectiveness data as specified by § 514.111 of this chapter, but may require bioequivalency and safety information.